Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAetna Kalbitor Precertification Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Kalbitor (ecallantide) Medication Precertification Request - Coverage Criteria

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Precertification form and requirements for Aetna coverage review of Kalbitor (ecallantide) for treatment of acute hereditary angioedema (HAE) attacks; used by prescribing and dispensing providers to request authorization or continuation of therapy.

    Policy Summary
    PayerAetna
    PolicyKalbitor (ecallantide) Medication Precertification Request - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrecertification must be requested via phone or fax using this form prior to administration or dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 pagesform length
    1-866-752-7021precert phone
    1-888-267-3277

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    precert fax
    Part BMedicare instruction

    Coverage Determinations

    Coverage criteria for Kalbitor (ecallantide)

    Covered when ALL of the following are documented:

    Diagnosis: Documented use for treatment of acute hereditary angioedema (HAE) attacks

    Form requires indication checkbox confirming use for acute HAE attacks

    Diagnostic confirmation: Laboratory confirmation of HAE with C1‑INH deficiency or dysfunction (C1‑INH antigenic level below lab lower limit OR normal antigenic level with low C1‑INH functional level [functional C1‑INH <50% or below lab lower limit]) OR genetic confirmation of HAE with normal C1‑INH (documented pathogenic mutation such as F12, angiopoietin‑1, plasminogen, KNG1, HS3ST6, or MYOF)C1‑INH functional <50% or below lab lower limit

    Form contains checkboxes to indicate which diagnostic criteria apply

    Prescriber specialty: Prescribed by or in consultation with a clinician who specializes in management of hereditary angioedema (HAE)

    Form asks whether prescriber specializes in HAE management

    Prior therapy or concomitant therapy: One of the following: a) Documentation that angioedema was refractory to a trial of high‑dose antihistamine therapy (e.g., cetirizine 40 mg/day or equivalent) for at least one month and family history of angioedema, OR b) Indication that the requested drug will be used in combination with other acute HAE medications (e.g., Berinert, Firazyr, Ruconest)cetirizine 40 mg/day (or equivalent) for ≥1 month

    Form asks about prior high‑dose antihistamine trial, family history, and concomitant acute HAE therapies; responses may inform coverage decisions

    Continuation of therapy: For continuation requests, documentation of reduction in severity and/or duration of acute attacks and dates of prior treatment

    Form includes fields asking whether attacks have decreased and requests last treatment date and outcomes

    This precertification form is intended specifically for requests to use Kalbitor (ecallantide) for the treatment of acute hereditary angioedema (HAE) attacks. The form requires the requester to indicate whether the drug is being used for treatment of acute HAE attacks and includes fields for product dose, frequency, and diagnosis codes to support that indication.

    The form asks for documentation that the angioedema is refractory to a trial of high‑dose antihistamine therapy (e.g., cetirizine 40 mg/day or equivalent) for at least one month and for supporting diagnostic confirmation of HAE. Requests where angioedema is not refractory to high‑dose antihistamines or where appropriate laboratory or genetic diagnostic confirmation is not provided may not meet the requirements on this form.

    Billing and Diagnosis Codes

    Administration codesModifier
    Administration code(s) (CPT)Form field requesting administration CPT codes
    ICD diagnosis codesICD-10
    Primary ICD CodePrimary diagnosis code field
    Secondary ICD CodeSecondary diagnosis code field
    Other ICD CodeOther diagnosis code field
    High‑dose antihistamine trial — inv-06
    Required trial dose and durationCetirizine 40 mg per day (or equivalent) for at least one month
    Purpose of trialDocument angioedema refractory to high-dose antihistamine therapy as part of precertification assessment
    Form checkbox triggerForm includes a checkbox specifically asking whether angioedema was refractory to a trial of high‑dose antihistamine therapy
    Equivalency note‘Or the equivalent’ indicates other antihistamines at an equivalent high‑dose may be considered
    Use in coverage decisionInformation about high‑dose antihistamine trial may be required to support medical necessity determinations

    Provider Requirements & Submission Instructions

    Prior Authorization

    Precertification required

    Precertification must be requested prior to administration or dispensing. Use the Aetna precertification phone or fax and submit this completed form when requesting authorization for Kalbitor (ecallantide).

    Step Therapy

    Prior trial and prophylaxis considerations

    The form asks whether prophylactic treatment has been considered and documents if angioedema was refractory to a trial of high‑dose antihistamine therapy (cetirizine 40 mg/day or equivalent for at least one month); this information may be required for coverage decisions.

    • Indicate if prophylactic treatment was considered (Yes/No).
    • Document if angioedema was refractory to high‑dose antihistamine (cetirizine 40 mg/day or equivalent) for ≥1 month.

    Clinical Background

    Ecallantide (Kalbitor) is requested on this form for the management of acute hereditary angioedema (HAE) attacks. The form collects diagnostic information to confirm HAE due to C1‑INH deficiency or dysfunction (including a C1‑INH antigenic level below the laboratory lower limit of normal or a C1‑INH functional level less than 50% or below the laboratory lower limit of normal) or genetic confirmation for HAE with normal C1‑INH (specified gene mutations). The form also asks whether the prescriber specializes in HAE management and whether the drug will be used in combination with other acute HAE therapies.

    Definitions

    HAE with C1‑INH deficiency or dysfunction — inv-12
    Diagnostic criterionC1 inhibitor (C1‑INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test
    Alternate functional criterionNormal C1‑INH antigenic level with a low C1‑INH functional level (functional C1‑INH <50% or below the laboratory lower limit of normal)
    Documentation requirementLaboratory confirmation of low antigenic or low functional C1‑INH must be indicated on the form
    ApplicabilityApplies to diagnosis of HAE with C1‑INH deficiency or dysfunction
    HAE with normal C1‑INH — inv-13
    Genetic confirmationF12, angiopoietin‑1, plasminogen, kininogen‑1 (KNG1), HS3ST6, or MYOF gene mutation confirmed by genetic testing
    Policy Summary
    PayerAetna
    PolicyKalbitor (ecallantide) Medication Precertification Request - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrecertification must be requested via phone or fax using this form prior to administration or dispensing.
    SourceLink
    On This Page
    Coverage DeterminationsBilling and Diagnosis CodesProvider Requirements & Submission InstructionsClinical BackgroundDefinitions
    Documentation Required

    Required clinical and administrative documentation

    Complete patient, insurance, prescriber and dispensing provider information and product details are required; include documentation that the request is for treatment of acute HAE attacks and diagnostic confirmation (C1‑INH antigenic or functional levels or genetic testing), dates of prior treatment and response for continuation requests.

    • Form fields for patient name, DOB, phone and start/last treatment dates must be completed.
    • Indicate indication (acute HAE attacks), prescriber specialty, and required diagnostic test results (C1‑INH antigenic/functional levels or relevant genetic testing).
    • For continuation, document reduction in severity/duration of attacks and prior treatment dates.
    Denial Risk

    Incomplete or false information may lead to denial

    Failure to provide complete and legible clinical information or knowingly submitting materially false or concealed information may result in denial, requests for additional information, or civil/criminal penalties.

    • Incomplete or illegible submissions may prompt denial or further review.
    • Providing materially false information may be considered fraud and carry penalties.
    Diagnostic categoryUsed to confirm diagnosis of hereditary angioedema (HAE) with normal C1‑INH
    Form fieldForm contains a checkbox to indicate HAE with normal C1‑INH and to list the specific gene mutation confirmed by testing
    Examples listedSpecifically lists F12, angiopoietin‑1, plasminogen, KNG1, HS3ST6, and MYOF as detectable mutations